- Home
- DGICA vs AKBA Comparison
DGICA vs AKBA Comparison
Compare DGICA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- AKBA
- Stock Information
- Founded
- DGICA 1986
- AKBA 2007
- Country
- DGICA United States
- AKBA United States
- Employees
- DGICA N/A
- AKBA N/A
- Industry
- DGICA Property-Casualty Insurers
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- AKBA Health Care
- Exchange
- DGICA Nasdaq
- AKBA Nasdaq
- Market Cap
- DGICA 705.0M
- AKBA 729.1M
- IPO Year
- DGICA N/A
- AKBA 2014
- Fundamental
- Price
- DGICA $20.00
- AKBA $1.66
- Analyst Decision
- DGICA Hold
- AKBA Strong Buy
- Analyst Count
- DGICA 1
- AKBA 6
- Target Price
- DGICA $18.00
- AKBA $6.25
- AVG Volume (30 Days)
- DGICA 110.3K
- AKBA 6.4M
- Earning Date
- DGICA 10-30-2025
- AKBA 11-10-2025
- Dividend Yield
- DGICA 3.65%
- AKBA N/A
- EPS Growth
- DGICA 219.91
- AKBA N/A
- EPS
- DGICA 2.38
- AKBA N/A
- Revenue
- DGICA $987,826,105.00
- AKBA $225,071,000.00
- Revenue This Year
- DGICA $2.26
- AKBA $53.38
- Revenue Next Year
- DGICA $3.46
- AKBA $30.53
- P/E Ratio
- DGICA $8.39
- AKBA N/A
- Revenue Growth
- DGICA 0.89
- AKBA 32.49
- 52 Week Low
- DGICA $14.17
- AKBA $1.52
- 52 Week High
- DGICA $21.12
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- DGICA 64.30
- AKBA 28.70
- Support Level
- DGICA $19.42
- AKBA $1.57
- Resistance Level
- DGICA $20.00
- AKBA $1.89
- Average True Range (ATR)
- DGICA 0.48
- AKBA 0.16
- MACD
- DGICA 0.12
- AKBA -0.06
- Stochastic Oscillator
- DGICA 97.53
- AKBA 5.94
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.